+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Sjögren's syndrome: managed care data from a large United States population highlight real-world health care burden and lack of treatment options



Sjögren's syndrome: managed care data from a large United States population highlight real-world health care burden and lack of treatment options



Clinical and Experimental Rheumatology (): -



To better understand the real-world characteristics and costs of Sjögren's syndrome (SS). Analysing the MarketScan Commercial Claims database from Jan. 1, 2006 to Dec. 31, 2011, we identified 10,414 patients ≥18 years old newly diagnosed with SS. Patient characteristics, drugs (commonly used for SS), resource utilisation, and medical costs were evaluated for 12 months pre- and post-diagnosis. Mean age was 55 years; 90% were female. At diagnosis, SS patients were most often seen by rheumatologists (39%) or internists (14.2%); the most common concurrent autoimmune conditions were rheumatoid arthritis (17.9%) and systemic lupus erythematosus (14.6%). Other common comorbidities were hypertension (37.6%), osteoarthritis (31.4%), and hyperlipidaemia/dyslipidaemia (30.3%). Post diagnosis of SS, claims for myocardial infarction and coronary artery bypass graft doubled. Medications of interest prescribed post-diagnosis were eye/mouth drugs (32.2%) and synthetic immunosuppressants (32.1%). Biologic drugs were prescribed to a minority (TNF inhibitors, ~5.0%; non-TNF inhibitors, 1%). Of note, prescriptions for all systemic immunotherapies (synthetic and biologic) were significantly lower in the subgroup without concurrent autoimmune disease, and 15.1% of the overall population had no SS-related prescriptions. Post diagnosis, total medical resource utilisation and total medical costs increased (1.2 and 1.4-fold, respectively). In this retrospective, real-world analysis, medical claims in the first year after SS diagnosis revealed that cardiovascular (CV) events increased and all-cause healthcare costs grew by 40%. Pharmacologic management consisted primarily of low potency immunomodulation and symptomatic treatments. Systemic disease-modifying therapies were used mostly in patients who had another concurrent autoimmune disease, suggesting a lack of treatment options for SS.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 058863781

Download citation: RISBibTeXText

PMID: 27749234


Related references

Health care burden and treatment patterns in commercially insured children with chronic idiopathic/spontaneous urticaria: A real-world study in the United States. Allergy and Asthma Proceedings 39(3): 201-211, 2018

Mental health care quality under managed care in the United States: a view from the Health Employer Data and Information Set (HEDIS). American Journal of Psychiatry 159(5): 860-862, 2002

Direct economic burden of chronic hepatitis C virus in a United States managed care population. Journal of Clinical Gastroenterology 45(2): E17-E24, 2011

The United States health care system under managed care. How the commodification of health care distorts ethics and threatens equity. Health Care Analysis 7(4): 393-411, 2000

Treatment costs and health care utilization for patients with bipolar disorder in a large managed care population. Value in Health 11(3): 416-423, 2008

Real-World Patterns of Care for the Overactive Bladder Syndrome in the United States. Urology 87: 64-69, 2016

Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States. Journal of Medical Economics 15(5): 947-955, 2013

Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. Oncologist 18(1): 37-45, 2013

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. Journal of Managed Care Pharmacy 19(8): 621-630, 2014

Are managed care organizations in the United States impeding the delivery of primary care by nurse practitioners? A 2012 update on managed care organization credentialing and reimbursement practices. Population Health Management 16(5): 306-309, 2014

Extra Issue: Health and Health Care in the United States: Origins and Dynamics || The Rise and Fall of Managed Care. Journal of Health and Social Behavior 45: 76-86, 2004

Dosing patterns of three tumor necrosis factor blockers among patients with rheumatoid arthritis in a large United States managed care population. Current Medical Research and Opinion 29(5): 561-568, 2013

Impact of Managed Health Care on the United States: Implications for Universal Health Care System. Journal of Human Behavior in the Social Environment 19(7): 805-819, 2009

The Canadian health care system as a managed care model for the United States. Health Care Management 2(1): 183-190, 1995

Providing managed care options for a large population: evaluating the CHAMPUS reform initiative. Civilian Health and Medical Program of the Uniformed Services. Military Medicine 165(5): 403-410, 2000